{"id":5204,"date":"2026-04-01T17:15:06","date_gmt":"2026-04-01T17:15:06","guid":{"rendered":"http:\/\/www.youtubexyoutube.com\/?p=5204"},"modified":"2026-04-14T19:25:03","modified_gmt":"2026-04-14T19:25:03","slug":"russia-tests-groundbreaking-cancer-treatment","status":"publish","type":"post","link":"http:\/\/www.youtubexyoutube.com\/index.php\/2026\/04\/01\/russia-tests-groundbreaking-cancer-treatment\/","title":{"rendered":"Russia tests groundbreaking cancer treatment"},"content":{"rendered":"
The personalized drug will tackle a patient\u2019s stage three melanoma, with results expected in the coming months<\/strong><\/p>\n A Russian melanoma patient has received the first personalized cancer vaccine in what is hoped to be a breakthrough in the treatment of the disease, the Russian Health Ministry said in a statement to TASS on Wednesday.<\/p>\n Last year, the ministry approved two domestically-made medicines: Neooncovac, an mRNA-based vaccine for advanced melanoma, and Oncopept, a peptide treatment targeting aggressive colorectal tumors. Both began human pilot trials in 2025.<\/p>\n On Tuesday, Neooncovac was administered to its first clinical patient, a 60-year-old male with stage three skin cancer, according to Aleksandr Ginzburg, scientific director of the Gamaleya Research Institute of Epidemiology and Microbiology, which helped develop the breakthrough anti-tumor medicine.<\/p>\n \u201cSo far, he is doing well; there have been no adverse reactions to the drug,\u201d<\/em> Ginzburg told Russian news portal Gazeta.ru on Wednesday. \u201cHe is 60 years old and has stage three melanoma with metastasis. The vaccine specifically helps fight metastases.\u201d<\/em><\/p>\n Samples were taken from the patient\u2019s tumor and non-tumor tissue, and researchers analyzed the genome to create a customized vaccine that trains the immune system to attack cancer cells, Ginzburg explained.<\/p>\n